Richard Idro, Rodney Ogwang, Ronald Anguzu, Pamela Akun, Albert Ningwa, Catherine Abbo, Maria P Giannoccaro, Joseph Kubofcik, Amos D Mwaka, Phellister Nakamya, Bernard Opar, Mark Taylor, Thomas B Nutman, Alison Elliott, Angela Vincent, Charles R Newton, Kevin Marsh
BACKGROUND: Nodding syndrome is a poorly understood neurological disorder that predominantly occurs in Africa. We hypothesised that nodding syndrome is a neuroinflammatory disorder, induced by antibodies to Onchocerca volvulus or its Wolbachia symbiont, cross-reacting with host neuronal proteins (HNPs), and that doxycycline can be used as treatment. METHODS: In this randomised, double-blind, placebo-controlled, phase 2 trial, we recruited participants from districts affected by nodding syndrome in northern Uganda...
May 13, 2024: Lancet Global Health